{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T09:51:05Z","timestamp":1720605065803},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[1993,10,1]],"date-time":"1993-10-01T00:00:00Z","timestamp":749433600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[1993,10]]},"DOI":"10.1007\/bf00315391","type":"journal-article","created":{"date-parts":[[2004,10,12]],"date-time":"2004-10-12T14:25:27Z","timestamp":1097591127000},"page":"247-253","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacokinetics and haemodynamic effects of a single oral dose of the novel ACE inhibitor spirapril in patients with chronic liver disease"],"prefix":"10.1007","volume":"45","author":[{"given":"S.","family":"Kr\ufffdhenb\ufffdhl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Grass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Surve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Kutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Reichen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","first-page":"287","volume":"34","author":"KH Beyer","year":"1982","unstructured":"Beyer KH, Peuler JD (1982) Hypertension: perspectives. Pharmacol Rev 34: 287?313","journal-title":"Pharmacol Rev"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2165\/00003495-198427030-00006","volume":"27","author":"CI Johnston","year":"1984","unstructured":"Johnston CI, Arnolda L, Hiwatari M (1984) Angiotensin-converting enzyme inhibitors in the treatment of hypertension. Drugs 27: 271?277","journal-title":"Drugs"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","volume":"316","author":"The Consensus Trial Study Group","year":"1987","unstructured":"The Consensus Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (Consensus). N Engl J Med 316: 1429?1435","journal-title":"N Engl J Med"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"The SOLVD Investigators","year":"1991","unstructured":"The SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325: 293?302","journal-title":"N Engl J Med"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","volume":"325","author":"JN Cohn","year":"1991","unstructured":"Cohn JN, Johnson G, Ziesche S (1991) A comparison of enalapril with hydralazine-isosorbide dinatrate in the treatment of chronic congestive heart failure. N Engl J Med 325: 303?310","journal-title":"N Engl J Med"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"198","DOI":"10.2165\/00003495-198631030-00002","volume":"31","author":"PA Todd","year":"1986","unstructured":"Todd PA, Heel RC (1986) Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 31: 198?248","journal-title":"Drugs"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/bmj.296.6622.618","volume":"296","author":"A Breckenridge","year":"1988","unstructured":"Breckenridge A (1988) Angiotensin converting enzyme inhibitors. BMJ 296: 618?620","journal-title":"BMJ"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0031-6989(88)80605-2","volume":"20","author":"A Monopoli","year":"1988","unstructured":"Monopoli A, Forlani A, Milani S, Ongini E (1988) Antihypertensive effect of spirapril and felodipine during repeated administration to spontaneously hypertensive rats. Pharmacol Res Commun 20: 37?47","journal-title":"Pharmacol Res Commun"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1097\/00005344-198706107-00020","volume":"10","author":"EJ Sybertz","year":"1987","unstructured":"Sybertz EJ, Watkins RW, Ahn HS, Baum T, La-Rocca P, Patrick J, Leitz F (1987) Pharmacologic, metabolic and toxicologic profile of spirapril (SCH 33844), a new angiotensin converting inhibitor. J Cardiovasc Pharmacol 10: S105-S108","journal-title":"J Cardiovasc Pharmacol"},{"key":"CR10","first-page":"216","volume":"286","author":"EJ Sybertz","year":"1987","unstructured":"Sybertz EJ, Baum T, Ahn HS, Desiderio DM, Pula KK, Tedesco R, Washington P, Sabin C, Smith E, Becker F (1987) Angiotensin converting enzyme inhibitory activity of SCH 33844 (spirapril) in rats, dogs and monkeys. Arch Int Pharmacodyn Ther 286: 216?229","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"S302","DOI":"10.1097\/00004872-198900076-00147","volume":"7","author":"AH Meiracker Van den","year":"1989","unstructured":"Van den Meiracker AH, Man in't Veld AJ, Ritsema van Eck HJ, Schalekamp MA (1989) Comparison of the acute and chronic antihypertensive effect of two once-daily doses of spirapril by invasive twenty-four-hour ambulatory blood pressure monitoring. J Hypertens 7: S302-S303","journal-title":"J Hypertens"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/00005344-199110000-00019","volume":"18","author":"SA Broek Van den","year":"1991","unstructured":"Van den Broek SA, van Bruggen A, de Graeff PA, Hillege H, van Gilst WH, Wesseling H, Lie KI (1991) The acute hemodynamic, hormonal, and pharmacokinetic properties of oral spirapril in patients with moderate to severe heart failure. J Cardiovasc Pharmacol 18: 614?621","journal-title":"J Cardiovasc Pharmacol"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/00005344-198711000-00017","volume":"10","author":"RP Hof","year":"1987","unstructured":"Hof RP, Hof-Miyashita A, Evenou JP (1987) Hemodynamic effects of a new angiotensin converting enzyme inhibitor, spirapril, in sodium loaded and sodium depleted rabbits. J Cardiovasc Pharmacol 10: 599?606","journal-title":"J Cardiovasc Pharmacol"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1021\/jm00127a033","volume":"32","author":"EM Smith","year":"1989","unstructured":"Smith EM, Swiss GF, Neustadt BR, McNamara P, Gold EH, Sybertz EJ, Baum T (1989) Angiotensin converting enzyme inhibitors: spirapril and related compounds. J Med Chem 32: 1600?1606","journal-title":"J Med Chem"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/00007691-199206000-00010","volume":"14","author":"M Hossein-Nia","year":"1992","unstructured":"Hossein-Nia M, Surve A, Weglein R, Gerbeau C, Holt D (1992) Radioimmunoassays for spirapril and its active metabolite spiraprilat: performance and application. Ther Drug Monit 14: 234?242","journal-title":"Ther Drug Monit"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1748-1716.1963.tb02638.x","volume":"58","author":"N Tygstrup","year":"1963","unstructured":"Tygstrup N (1963) Determination of hepatic galactose elimination capacity after a single intravenous injection in man. Acta Physiol Scand 58: 162?172","journal-title":"Acta Physiol Scand"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3109\/00365528509088884","volume":"20","author":"A Wahll\u00e4nder","year":"1985","unstructured":"Wahll\u00e4nder A, Renner E, Preisig R (1985) Fasting plasma caffeine concentration. A guid to the severity of chronic liver disease. Scand J Gastroenterol 20: 1133?1141","journal-title":"Scand J Gastroenterol"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/cpt1976204484","volume":"20","author":"J Bircher","year":"1976","unstructured":"Bircher J, K\u00fcpfer A, Gikalov I, Preisig R (1976) Aminopyrine demethylation measured by breath analysis in cirrhosis. Clin Pharmacol Ther 20: 484?492","journal-title":"Clin Pharmacol Ther"},{"key":"CR19","volume-title":"Statistical methods in medical research","author":"P Armitage","year":"1987","unstructured":"Armitage P, Berry G (1987) Statistical methods in medical research. Blackwell, Oxford London Edinburgh"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2165\/00003088-197904060-00002","volume":"4","author":"TF Blaschke","year":"1979","unstructured":"Blaschke TF, Rubin PC (1979) Hepatic first-pass metabolism in liver disease. Clin Pharmacokinet 4: 423?432","journal-title":"Clin Pharmacokinet"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-198409010-00001","volume":"9","author":"SM Pond","year":"1984","unstructured":"Pond SM, Tozer NT (1984) First-pass elimination. Basic concepts and clinical consequences. Clin Pharmacokinet 9: 1?25","journal-title":"Clin Pharmacokinet"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/cpt1975184377","volume":"18","author":"GR Wilkinson","year":"1975","unstructured":"Wilkinson GR, Shand DG (1975) A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18: 377?390","journal-title":"Clin Pharmacol Ther"},{"key":"CR23","first-page":"501","volume":"196","author":"BH Lauterburg","year":"1976","unstructured":"Lauterburg BH, Bircher J (1976) Exspiratory measurement of maximal aminopyrine demethylation in vivo: effect of phenobarbital, partial hepatectomy, portacaval shunt and bile duct ligation in the rat. J Pharmacol Exp Ther 196: 501?509","journal-title":"J Pharmacol Exp Ther"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1172\/JCI113828","volume":"82","author":"J Reichen","year":"1988","unstructured":"Reichen J, Egger B, Ohara N, Zeltner TB, Zysset T, Zimmermann A (1988) Determinants of hepatic function in liver cirrhosis in the rat. Multivariate analysis. J Clin Invest 82. 2069?2076","journal-title":"J Clin Invest"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1432-1033.1973.tb02891.x","volume":"36","author":"R Arndt","year":"1973","unstructured":"Arndt R, Heymann E, Junge W, Krisch K, Hollandt H (1973) Purification and molecular properties of an unspecific carboxylesterase (E1) from rat-liver microsomes. Eur J Biochem 36: 120?128","journal-title":"Eur J Biochem"},{"key":"CR26","first-page":"294","volume":"257","author":"KS Pang","year":"1991","unstructured":"Pang KS, Barker F, Cherry WF, Goresky CA (1991) Esterases for enalapril hydrolysis are concentrated in the perihepatic venous region of the rat liver. J Pharmacol Exp Ther 257: 294?301","journal-title":"J Pharmacol Exp Ther"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0016-5085(84)80022-0","volume":"86","author":"H Ohkubo","year":"1984","unstructured":"Ohkubo H, Okuda K, Iida S, Ohnishi K, Ikawa S, Makino I (1984) Role of portal and splenic vein shunts and impaired hepatic extraction in the elevated serum bile acids in liver cirrhosis. Gastroenterology 86: 514?520","journal-title":"Gastroenterology"},{"key":"CR28","first-page":"S1","volume":"105","author":"G Paumgartner","year":"1975","unstructured":"Paumgartner G (1975) The handling of indocyanine green by the liver. Schweiz Med Wochenschr 105: S1-S30","journal-title":"Schweiz Med Wochenschr"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/clpt.1989.87","volume":"45","author":"A Ohnishi","year":"1989","unstructured":"Ohnishi A, Tsuboi Y, Ishizaki T, Kubota K, Ohno T, Yoshida H, Kanezaki A, Tanaka T (1989) Kinetics and dynamics of enalapril in patients with liver cirrhosis. Clin Pharmacol Ther 45: 657?665","journal-title":"Clin Pharmacol Ther"},{"key":"CR30","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1476-5381.1990.tb12057.x","volume":"100","author":"RD Carr","year":"1990","unstructured":"Carr RD, Cooper AE, Hutchinson R, Mann J, O'Conner SE, Robinson DH, Wells E (1990) Preferential biliary elimination of FPL 63547, a novel inhibitor of angiotensin-converting enzyme, in the rat. Br J Pharmacol 100: 90?94","journal-title":"Br J Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00315391.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00315391\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00315391","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T09:56:31Z","timestamp":1585907791000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00315391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993,10]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1993,10]]}},"alternative-id":["BF00315391"],"URL":"https:\/\/doi.org\/10.1007\/bf00315391","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[1993,10]]}}}